Dealing with hERG liabilities early: diverse approaches to an important goal in drug development.
Guth
B D
BD
General Pharmacology Group, Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. brian.guth@boehringer-ingelheim.com
Rast
G
G
D000818:Animals; D002986:Clinical Trials as Topic; D015195:Drug Design; D064420:Drug-Related Side Effects and Adverse Reactions; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D018570:Risk Assessment / Q000379:methods
D051638:Ether-A-Go-Go Potassium Channels